CLAIMS

1. Use of an antibody or functional part, derivative and/or analogue thereof that comprises a variable domain that binds an extracellular part of EGFR and an extracellular domain of LGR5 in the manufacture of a medicament for the treatment of a cancer in a human subject, wherein the medicament is to be administered with an immune checkpoint inhibitor.

2. Use of an immune checkpoint inhibitor in the manufacture of manufacture of a medicament for the treatment of a cancer in a human subject, wherein the medicament is to be administered with an antibody or functional part, derivative and/or analogue thereof that comprises a variable domain that binds an extracellular part of EGFR and an extracellular domain of LGR5.

3. Use of an immune checkpoint inhibitor and an antibody or functional part, derivative and/or analogue thereof that comprises a variable domain that binds an extracellular part of EGFR and an extracellular domain of LGR5 in the manufacture of a medicament for the treatment of a cancer in a human subject.

4. The use of any one of the preceding claims, wherein the cancer is an adenocarcinoma, a squamous cell carcinoma, or a head and neck cancer, including squamous cell carcinoma of the head and neck (SCCHN).

5. The use of any one of the preceding claims, wherein the cancer is squamous cell carcinoma of the head and neck (SCCHN).

6. The use of any one of the preceding claims, wherein the cancer is a cancer of the pharynx (including nasopharynx, oropharynx and hypopharynx), oral cavity, larynx, paranasal sinuses, nasal cavity or salivary glands.

7. The use of any one of the preceding claims, wherein said immune checkpoint inhibitor comprises a PD-L1, PD-L2 or PD-1 inhibitor.

8. The use of any one of the preceding claims, wherein the immune checkpoint inhibitor is an antibody that binds PD-L1, PD-L2 or PD-1.

9. The use of any one of the preceding claims, wherein the immune checkpoint inhibitor is pembrolizumab.

10. The use of any one of the preceding claims, wherein said subject has not received prior anti-cancer treatment for treatment of said cancer.

11. The use of any one of the preceding claims, wherein the antibody or functional part, derivative and/or analogue thereof, is a bispecific antibody.

12. The use of claim 11, wherein the antibody or functional part, derivative and/or analogue thereof comprises a variable domain that binds an extracellular part of EGFR, said variable domain comprising at least the CDR1, CDR2 and CDR3 sequences of the VH of MF3755, defined by SEQ ID NO: 4; and comprises a variable domain that binds an extracellular domain of LGR5, said variable domain comprising at least the CDR1, CDR2 and CDR3 sequences of the VH of MF5816, defined by SEQ ID NO:13; wherein both said variable domains that bind EGFR and that bind LGR5 comprise the CDR1, CDR2 and CDR3 regions of the light chain variable region defined by SEQ ID No. 108.

13. The use of any one of claims 11-12, wherein said variable domain that binds EGFR comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:24, a CDR2 comprising the amino acid sequence of SEQ ID NO:24, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 26;
said variable domain that binds LGR5 comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:87, a CDR2 comprising the amino acid sequence of SEQ ID NO:89, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 91; and
said light chain variable region comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:111, a CDR2 comprising the amino acid sequence of SEQ ID NO:112, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 113.

14. The use of any one of claims 11-13, wherein the variable domain that binds EGFR comprises the amino acid sequence of VH chain MF3755 defined by SEQ ID No. 4; or the amino acid sequence of VH chain MF3755 having at most 15, preferably not more than 10, 9, 8 ,7, 6, 5, 4, 3, 2, 1 and preferably having not more than 5, 4, 3, 2 or 1 amino acid modifications, including insertions, deletions, substitutions or a combination thereof

with respect to said VH; and wherein the variable domain that binds LGR5 comprises the amino acid sequence of VH chain MF5816 defined by SEQ ID No. 13; or the amino acid sequence of VH chain MF5816 having at most 15, preferably not more than 10, 9, 8,7, 6, 5, 4, 3, 2, 1 and preferably having not more than 5, 4, 3, 2 or 1 amino acid modifications, including insertions, deletions, substitutions or a combination thereof with respect to said VH.

15. The use of any one of claims 11-14, wherein the variable domain that binds EGFR comprises the amino acid sequence of VH chain MF3755 defined by SEQ ID No. 4 and wherein the variable domain that binds LGR5 comprises the amino acid sequence of VH chain MF5816 defined by SEQ ID No. 13.

16. The use of any one of claims 11-15, wherein both said variable domains that bind EGFR and that bind LGR5 comprise the light chain variable region defined by SEQ ID No. 108, which variable light chain region comprises from 0 to 10 amino acid insertions, deletions, substitutions, additions or a combination thereof, wherein the amino acid insertions, deletions and substitutions are not present in the CDR1, CDR2 and CDR3 light chain variable regions.

17. The use of any one of claims 11-16, wherein both said variable domains that bind EGFR and that bind LGR5 comprise the light chain variable region defined by SEQ ID No. 108.

18. The use of any one of the preceding claims, wherein the antibody that comprises a variable domain that binds an extracellular part of EGFR, is petosemtamab.

19. The use of claim 18, wherein said treatment comprises providing a biweekly dose of 1500 mg of petosemtamab to the subject.

20. The use of any one of the preceding claims, wherein said treatment comprises administration of a dose of 400 mg of pembrolizumab as immune check point inhibitor once every six weeks to the subject.

21. The use of any one of the preceding claims, wherein petosemtamab as the antibody that comprises a variable domain that binds an extracellular part of EGFR and pembrolizumab as the immune checkpoint inhibitor are to be sequentially administered.

22. The use of any one of the preceding claims, wherein if pembrolizumab as the immune checkpoint inhibitor and petosemtamab as the antibody that comprises a variable domain that binds an extracellular part of EGFR are to be administered on the same day, pembrolizumab is to be administered after petosemtamab.

23. The use of any one of the preceding claims, wherein the antibody or functional part, derivative and/or analogue thereof or the immune checkpoint inhibitor is to be provided intravenously to the subject.

24. The use of any one of the preceding claims, wherein the antibody or functional part, derivative and/or analogue thereof that comprises a variable domain that binds an extracellular part of EGFR is ADCC enhanced.

25. The use of any one of the preceding claims, wherein the antibody or functional part, derivative and/or analogue thereof that comprises a variable domain that binds an extracellular part of EGFR is afucosylated.

26. The use of any one of the preceding claims, wherein the cancer is recurrent, unresectable, locally advanced and/or metastatic cancer.

27. The use of any one of the preceding claims, wherein the treatment comprises or is preceded by a step of diagnosing the subject or the cancer for PD-L1 expression.

28. The use of claim 26, wherein diagnosing for PD-L1 expression is by immune histochemistry (IHC).

29. The use of any one of the preceding claims, wherein the cancer has a Combined Positive Score (CPS) for PD-L1 expression of 1 or more, but not more than 100.

30. A kit of parts comprising an antibody or functional part, derivative and/or analogue thereof that comprises a variable domain that binds an extracellular part of

EGFR and an extracellular part of LGR5 as defined in any one of the preceding claims, an immune checkpoint inhibitor as defined in any one of the preceding claims and instructions for use of said antibody or functional part, derivative and/or analogue thereof and for use of said immune checkpoint inhibitor.

31. The kit according to claim 30, wherein the antibody is petosemtamab and the instructions comprise instructions for dosing at 1500 mg once every two weeks.

32. The kit according to claim 30 or 31, wherein the immune checkpoint inhibitor is pembrolizumab and instructions for use comprise instructions for dosing at 400 mg once every six weeks.

33. The kit of parts according to any one of claims 30-32, wherein the kit comprises instructions for use of the antibody or functional part, derivative and/or analogue thereof and the immune checkpoint inhibitor in the treatment of head and neck cancer.

34. The use of any one of claims 1-29, wherein the antibody or functional part, derivative and/or analogue thereof and the immune checkpoint inhibitor are to be administered as a combination.

35. The use of any one of claims 1-29, wherein the immune checkpoint inhibitor is to be administered simultaneously or sequentially with the antibody or functional part, derivative and/or analogue thereof.

36. Use of an antibody or functional part, derivative and/or analogue thereof that comprises a variable domain that binds an extracellular part of EGFR as defined in any one of claims 1-35, in the manufacture of a medicament for the treatment of cancer in a human subject, wherein the subject has been, is being, or will be administered an immune checkpoint inhibitor, as defined in any one of claims 1-29.

37. Use of an immune checkpoint inhibitor, as defined in any one of claims 1-29, in the manufacture of a medicament for the treatment of cancer in a human subject, wherein the subject has been, is being, or will be administered an antibody or functional part, derivative and/or analogue thereof that comprises a variable domain that binds an extracellular part of EGFR as defined in any one of claims 1-29 .